TRYPSIN VI is our pancreatic enzyme extract comprising high concentration of both Trypsin (EC 18.104.22.168) and Chymotrypsin (EC 22.214.171.124). Together these serine proteases form the fundamental component of the physiological digestion of protein in humans. TRYPSIN VI is used to effectively mimic digestive processes, finding broad ranging applications across pharmaceutical, food, and feed industries.
TRYPSIN VI is ideally suited to food applications due to its proteolytic functionality. TRYPSIN VI is used to improve the digestibility of infant formula, as well as in the production of hypoallergenic formula.
The proteolytic functionality of TRYPSIN VI make it highly valued for whey protein hydrolysis, facilitating the rapid absorption of nutrients whilst reducing allergenicity of milk proteins. This property can be taken advantage of for reducing oiling-out in cheese making, tenderising meat and seafood, and improving food digestibility.
As an excellent source of trypsin and chymotrypsin, TRYPSIN VI has found nutraceutical use as a digestive supplement and anti-inflammatory treatment for both human and veterinary applications.
TRYPSIN VI predominant formulations are available that take advantage of their proteolytic properties to reduce inflammation, oedema, and subcutaneous bruising following minor contusions of the skin and soft tissues.
Specifications (USP units/mg):
Activity in USP units/mg
Trypsin: ≥ 2500 U/mg
Chymotrypsin: ≥ 250 U/mg
Medical, Pharmaceutical, and Research
|Cell and Tissue Culture
|Diabetes & Ophthalmic research
|USP / EP guideline conformance
|Reduce Oedema and Bruising
Food Processing, Infant Formula & Dietary Supplements
|Whey Protein Hydrolysis
|Production of Infant Formula
|Production of Hypoallergenic Infant Formula
|Meat and Seafood Tenderisation
|Enhancement of Food Digestibility
Neova Technologies Inc., part of Bioseutica® group, has been extracting pancreatic enzymes for over 25 years. As one of the largest global manufacturers of porcine-derived enzymes, we have the experience to tailor our preparations to the exacting specifications of our customers. Contact us using the form below to discuss your specific requirements.
No Warranty: The information contained herein is provided in good faith and, to the best of our knowledge, is true and correct. However, no warranty or guarantee is implied or inferred and the information may be subject to change without prior notice. Neova Technologies Inc.’s products are sold with the understanding that the purchaser will conduct tests to determine the suitability of these products for their particular use.
Bioseutica® is proud to inform that the European Food Safety Authority (EFSA) has just issued its scientific opinions on two applications submitted by NEOVA Technologies Inc (a BIOSEUTICA group company) related to the food enzymes
- trypsin and chymotrypsin from porcine pancreas (our Brand name TRYPSIN VI)
- trypsin, chymotrypsin, elastase and carboxypeptidase from porcine pancreas (our Brand name TRYPSIN SE)
The EFSA conclusions for the 2 enzymes are:
“Based on the origin of the food enzyme from edible parts of animals, the data provided by the applicant, supported by the evaluation of clinical studies with pharmaceutical preparations based on pancreatic enzymes, the Panel concluded that the porcine pancreatic enzymes do not give rise to safety concern under the intended conditions of use.”
Access to the 2 scientific opinions published on the EFSA Journal Vol. 19, No. 1, January 2021 is freely available here.
Based on these EFSA safety evaluations, the 2 food enzymes will be approved by the European Commission by means of their inclusion into the Union list of food enzymes, expected in 2023.
These positive opinions are a confirmation of the commitment the Bioseutica group has to the quality and safety of its products, as well as to our dedication to service to our customers and end-users.